Greenwich LifeSciences Expands Phase III FLAMINGO-01 Breast Cancer Trial to Austria

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-0...

October 10, 2025 | Friday | News
Roquette Unveils Novel Excipient KLEPTOSE® Crysmeb to Advance Drug Solubility and Delivery Performance

Roquette, a global leader in plant-based ingredients and pharmaceutical excipients for the health and nutrition sectors, today, celebrates the launch of ...

October 09, 2025 | Thursday | News
Axplora Announces €100 Million Global Investment to Strengthen API Manufacturing Leadership

Axplora, a global leader in small molecule API manufacturing and a trusted partner to the world’s most innovative pharmaceutical companies, today ann...

October 09, 2025 | Thursday | News
Lupin’s €190 Million Vision: Thierry Volle on Building a Global Ophthalmology Powerhouse

The €190 million acquisition of VISUfarma marks a pivotal moment in Lupin’s transformation into a global specialty-led biopharma. With VISUfarma...

October 08, 2025 | Wednesday | Interaction
OXB Expands Global CDMO Footprint with Acquisition of Resilience’s FDA-Approved Viral Vector Manufacturing Facility in North Carolina

OXB acquires Resilience’s site in North Carolina, an FDA-approved, commercial-scale viral vector manufacturing facility In line with OXB’...

October 08, 2025 | Wednesday | News
Invivyd Receives FDA Clearance to Advance REVOLUTION Program with Phase 3 DECLARATION and LIBERTY Trials for COVID Prevention

The DECLARATION (safety and efficacy vs. placebo) and LIBERTY (exploratory safety head-to-head and combination with mRNA-based COVID vaccination) clini...

October 07, 2025 | Tuesday | News
Advanz Pharma and Alvotech Secure EMA Acceptance for Xolair® Biosimilar AVT23

Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospita...

October 07, 2025 | Tuesday | News
Avobis Bio Earns FDA RMAT Designation for AVB-114 in Crohn’s Perianal Fistulas

Avobis Bio LLC, a clinical-stage company developing implantable cell therapies, announced  that the U.S. Food and Drug Administration ("FDA") has gr...

October 06, 2025 | Monday | News
Esperion Secures Key Patent Settlement with Dr. Reddy’s, Protecting NEXLETOL and NEXLIZET Until 2040

Esperion announced that it has entered into a settlement agreement with Dr. Reddy’s Laboratories, Inc. and its affiliate Dr. Reddy’s Laborato...

October 06, 2025 | Monday | News
Revvity and Profluent Lead the Next Frontier in Gene Editing with AI-Powered Precision

In conversation with BioPharma BoardRoom, Amanda Haupt, Business Unit Manager for Base Editing at Revvity, shares insights into how the com...

October 06, 2025 | Monday | Interaction
Sitryx Therapeutics Receives FDA Clearance to Advance SYX-5219 Into Phase 1b Trial for Atopic Dermatitis

SYX-5219 is a first-in-class oral PKM2 modulator designed to drive sustained disease remission across a range of autoimmune diseases Phase 1b trial to...

October 03, 2025 | Friday | News
Draig Therapeutics Secures FDA Clearance to Launch Phase 2 Trial of DT-101 for Major Depressive Disorder

DT-101 is designed to allow effective modulation of the AMPA receptor without compromising safety Phase 2 clinical trial initiation anticipated before...

October 03, 2025 | Friday | News
Igyxos Biotherapeutics Secures €5.7M France 2030 Grant to Advance Infertility Antibody Therapy

Igyxos Biotherapeutics, a biotechnology company dedicated to developing innovative monoclonal antibodies for infertility treatment, announced that it has...

October 03, 2025 | Friday | News
Kynexis Doses First Patient in Phase 2 Trial of KYN-5356 for Cognitive Impairment Associated with Schizophrenia

Kynexis, a clinical-stage biotechnology company focused on precision therapeutics for brain diseases, announced that the first patient has been dosed in ...

October 01, 2025 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close